Cargando…
Extrapolation in Practice: Lessons from 10 Years with Biosimilar Filgrastim
Biosimilar filgrastim (Sandoz) was approved in Europe in 2009 and, in 2015, was the first biosimilar approved in the USA. These authorizations were based on the “totality of evidence” concept, an approach that considers data from structural and functional characterization and comparability analysis...
Autores principales: | Gascon, Pere, Krendyukov, Andriy, Mathieson, Nicola, Natek, Maja, Aapro, Matti |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6875156/ https://www.ncbi.nlm.nih.gov/pubmed/31440986 http://dx.doi.org/10.1007/s40259-019-00373-2 |
Ejemplares similares
-
Treatment patterns and outcomes in patients with non‐small cell lung cancer receiving biosimilar filgrastim for prophylaxis of chemotherapy‐induced/febrile neutropaenia: Results from the MONITOR‐GCSF study
por: Aapro, Matti, et al.
Publicado: (2019) -
Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years’ Experience Gained
por: Aapro, Matti, et al.
Publicado: (2018) -
Development and 10-year history of a biosimilar: the example of Binocrit(®)
por: Aapro, Matti, et al.
Publicado: (2018) -
Extrapolation concept at work with biosimilar: a decade of experience in oncology
por: Krendyukov, Andriy, et al.
Publicado: (2018) -
Predictive modeling of the outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (MONITOR-GCSF study)
por: Aapro, M., et al.
Publicado: (2016)